Loading
RP
Ra Pharmaceuticals, Inc. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest, by NEW ENTERPRISE ASSOCIATES 13 LP, was filed 14 Dec 2018.
Ra Pharmaceuticals, Inc.: what insiders have been doing
Ra Pharmaceuticals, Inc. is a listed company. Filings by its managers are published through SEC (Form 4). No insider at Ra Pharmaceuticals, Inc. has published a filing in the past twelve months. The most recent one dates from 3 April 2020.
Our records for Ra Pharmaceuticals, Inc. go back to 2017, with 6 purchases and 47 sales on the open market in total.
This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Insider Decl.
99
Thresholds
n/a
Buy Volume
€70M
6 ops. · all time
Sell Volume
€13M
47 ops. · all time
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Last declaration on 3 April 2020
Declarations99 total
4,858,260 shares@ US$48.00100.0% of flowCommon StockSEC:0001104659-20-042762:0
14,492 shares@ US$48.0016.0% of flowCommon StockSEC:0001104659-20-042769:0
234,707 shares@ US$48.00100.0% of flowCommon StockSEC:0001104659-20-042773:0
10,823 shares@ US$48.00100.0% of flowCommon StockSEC:0001104659-20-042766:0
15,622 shares@ US$48.00100.0% of flowCommon StockSEC:0001104659-20-042772:0
12,595 shares@ US$48.0025.1% of flowCommon StockSEC:0001104659-20-042770:0
4,858,260 shares@ US$48.00100.0% of flowCommon StockSEC:0001104659-20-042764:0
2,973 shares@ US$48.0025.7% of flowCommon StockSEC:0001104659-20-042771:0
6,135,234 sharesCommon StockSEC:0001209191-20-022933:0
2,288 shares@ US$44.2517.7% of flowCOMMON STOCKSEC:0001104659-20-035492:0
9,206 shares@ US$5.601.2% of flowCOMMON STOCKSEC:0001104659-20-035491:1
10,595 shares@ US$45.1610.7% of flowCOMMON STOCKSEC:0001104659-20-035491:2
1,389 shares@ US$5.600.2% of flowCOMMON STOCKSEC:0001104659-20-035491:0
1,389 shares@ US$5.600.2% of flowCOMMON STOCKSEC:0001104659-20-023526:0
9,206 shares@ US$5.601.0% of flowCOMMON STOCKSEC:0001104659-20-023526:1
10,595 shares@ US$46.619.9% of flowCOMMON STOCKSEC:0001104659-20-023526:2
2,285 shares@ US$47.0215.3% of flowCOMMON STOCKSEC:0001104659-20-005636:0
1,389 shares@ US$5.600.1% of flowCOMMON STOCKSEC:0001104659-20-004828:0
9,206 shares@ US$5.600.9% of flowCOMMON STOCKSEC:0001104659-20-004828:1
10,595 shares@ US$46.959.0% of flowCOMMON STOCKSEC:0001104659-20-004828:2
10,000 shares@ US$2.870.8% of flowCOMMON STOCKSEC:0001104659-19-073911:0
10,000 shares@ US$47.0813.9% of flowCOMMON STOCKSEC:0001104659-19-073911:1
1,389 shares@ US$5.600.1% of flowCOMMON STOCKSEC:0001104659-19-073910:0
9,206 shares@ US$5.600.9% of flowCOMMON STOCKSEC:0001104659-19-073910:1
10,595 shares@ US$47.239.1% of flowCOMMON STOCKSEC:0001104659-19-073910:2
25 of 99 declarations
About Ra Pharmaceuticals, Inc.
Ra Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing treatments for autoimmune diseases and neurological disorders. It is listed on NASDAQ under the ticker XNAS.
